Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind, randomized, placebo-controlled study of olpasiran (AMG 890) in subjects with elevated lipoprotein(a)
2019-003688-23Phase 2Completed
- Sponsor
- Amgen
- Start
- Jun 2020
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atherosclerotic disease, lipoprotein(a) hyperlipoproteinemia (Lp(a)) and hyperlipidemia comparing Olpasiran Q12W with Placebo Q12W (2 arms). Primary endpoint: Percent change in lipoprotein(a) from baseline at week 36. Started Jun 2020; status: completed.
02
Drugs
olpasiran
03
Conditions
atherosclerotic diseaselipoprotein(a) hyperlipoproteinemia (Lp(a))hyperlipidemia
Beyond the preview
Go deeper on 2019-003688-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003688-23.